PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI) (the “Company”), a medical device and pharmaceutical company focused on advanced wound care, today announced that it closed an underwritten registered direct offering of 2,125,000 shares of common stock at a price of $9.25 per share on April 5, 2012. The Company plans to use the approximately $17.9 million in net proceeds for the continued development of DSC127 and for general corporate purposes.
“The proceeds from this offering will, in part, fund our Phase 3 trials with DSC127 for the treatment of diabetic foot ulcers, which we anticipate beginning in the second half of the year. With the expected closing of our acquisition of MedEfficiency later this month, this financing allows us to maintain a strong balance sheet as we continue down the path to becoming a leading provider of advanced wound care products for a rapidly growing and underserved patient population,” said Edward J. Quilty, chief executive officer of Derma Sciences.
Piper Jaffray & Co. acted as the sole underwriter of the offering. ROTH Capital Partners acted as financial advisor.
Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission at www.sec.gov, or from Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by email prospectus@pjc.com or by telephone at (800) 747-3924.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This offering may be made only by means of a prospectus supplement and accompanying base prospectus.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for accelerated wound healing and scar reduction, and is preparing to begin Phase 3 clinical trials. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention.
For more information please visit www.dermasciences.com.
Forward-Looking Statements
Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.